Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vasospasm, Intracranial Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Nitric Oxide Consumption as a Predictor of Vasospasm in Subarachnoid Hemorrhage

NCT07614906
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial

NCT03318783
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia, Vasospasm, Cerebral, Endothelial Dysfunction
Interventions
GSK2256294, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jun 10, 2026, 8:42 AM EDT
Terminated Phase 3 Interventional

Clazosentan in Aneurysmal Subarachnoid Hemorrhage

NCT00940095
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan 5 m/h, Clazosentan 15 mg/h, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
29
States / cities
Glendale, California • San Francisco, California • Stanford, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Jun 10, 2026, 8:42 AM EDT
Not yet recruiting Phase 4 Interventional

Lumbar Drain With Intrathecal Nicardipine in Aneurysmal Subarachnoid Hemorrhage

NCT07246629
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Normal Saline, Nicardipine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 10, 2026, 8:42 AM EDT
Not yet recruiting Not applicable Interventional

The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage

NCT06443177
View directory record Official record
Conditions
Vasospasm, Cerebral, Aneurysmal Subarachnoid Hemorrhage
Interventions
Vectris trial leads and stimulation, Sham
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 3 Interventional Results available

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain

NCT03585270
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Jun 10, 2026, 8:42 AM EDT
Active, not recruiting No phase listed Observational

Evaluation of Cerebral Spinal Fluid and Blood in Patients With Subarachnoid Hemorrhage

NCT00593268
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 1 Interventional

Remote Ischemic Preconditioning in Subarachnoid Hemorrhage

NCT01158508
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal, Subarachnoid Hemorrhage, Cerebral Vasospasm, Intracranial Aneurysm
Interventions
Remote ischemic preconditioning
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 3 Interventional

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

NCT00558311
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
11
States / cities
Phoenix, Arizona • Englewood, Colorado • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jun 10, 2026, 8:42 AM EDT
Suspended Phase 2 Interventional

Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin

NCT02501434
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial, Intracranial Aneurysm, Heparin-induced Thrombocytopenia Type II
Interventions
Continuous Low-Dose IV Unfractionated Heparin Infusion
Drug
Lead sponsor
Robert F. James
Other
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
New Haven, Connecticut • Gainesville, Florida • Tallahassee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jun 10, 2026, 8:42 AM EDT
Withdrawn Phase 2 Interventional

Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)

NCT02011321
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Cerebral Aneurysm, Vasospasm, Intracranial
Interventions
clevidipine
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jun 10, 2026, 8:42 AM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Nicardipine to Treat Cerebral Vasospasm

NCT01810302
View directory record Official record
Conditions
Cerebral Vasospasm
Interventions
Nicardipine hydrochloride, Preservative-free normal saline
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Jun 10, 2026, 8:42 AM EDT
Terminated Phase 2 Interventional Results available

Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions

NCT01845441
View directory record Official record
Conditions
Stroke, Brain Ischemia, Vasospasm, Intracranial, Hemorrhage, Intracranial
Interventions
Dexmedetomidine, Fentanyl, Midazolam
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Jun 10, 2026, 8:42 AM EDT
Terminated Not applicable Interventional Results available

Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage

NCT00487461
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions
Simvastatin 40 mg, Placebo, Simvastatin 80 mg
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Jun 10, 2026, 8:42 AM EDT
Enrolling by invitation Not applicable Interventional

Cervical Sympathetic Block in Patients With Cerebral Vasospasm

NCT05230134
View directory record Official record
Conditions
Anesthesia, Local, Cerebral Vasospasm, Subarachnoid Hemorrhage, Aneurysmal
Interventions
Cervical sympathetic block
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jun 10, 2026, 8:42 AM EDT
Terminated Phase 2 Interventional Results available

Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

NCT02712788
View directory record Official record
Conditions
Cerebral Vasospasm
Interventions
Milrinone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jun 10, 2026, 8:42 AM EDT
Completed No phase listed Observational Results available

Ventriculostomies in SAH: ICP Open or Not?

NCT00787020
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 4 Interventional Results available

Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm

NCT03377049
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal, Vasospasm, Cerebral
Interventions
Acetazolamide
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage

NCT00964548
View directory record Official record
Conditions
Cerebral Vasospasm After Subarachnoid Hemorrhage
Interventions
Dantrolene
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Jun 10, 2026, 8:42 AM EDT
Terminated Phase 2 Interventional Results available

Intravenous Nitrite Infusion for Reversal of Cerebral Vasospasm After Subarachnoid Hemorrhage

NCT02176837
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Sodium Nitrite
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 1Phase 2 Interventional

A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm

NCT00235963
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Delayed Vasospasm
Interventions
Simvastatin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2008 · Synced Jun 10, 2026, 8:42 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage

NCT01878136
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm, Cerebral Aneurysm, Hydrocephalus
Interventions
Tissue Plasminogen Activator
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Jun 10, 2026, 8:42 AM EDT
Terminated Phase 3 Interventional Results available

Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm

NCT00585559
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions
Placebos for acetaminophen and N-acetylcysteine, APAP 1 gm every 6 hours and N-acetylcysteine placebo, NAC IV infusion at 0.5 gm hourly and APAP placebo, APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly, APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
20 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Jun 10, 2026, 8:42 AM EDT
Active, not recruiting Phase 2 Interventional

Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)

NCT04876638
View directory record Official record
Conditions
Aneurysm, Ruptured, Vasospasm, Intracranial, Delayed Cerebral Ischemia, Blood Brain Barrier Defect
Interventions
Minocyclin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Jun 10, 2026, 8:42 AM EDT